MaxCyte, Inc. Director/PCA transaction initial notification (0553X)
December 16 2019 - 12:25PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 0553X
MaxCyte, Inc.
16 December 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director/PCA transaction initial notification
Gaithersburg, Maryland - 16 December 2019: MaxCyte (LSE: MXCT,
MXCS), the global cell-based therapies and life sciences company
announces that John Johnston, Non-Executive Director, has
transferred 17,041 ordinary shares of 0.1 pence each in the Company
(Ordinary Shares) to his wife, Karin Johnston, a person closely
associated (PCA). The transfer took place on 14 December 2019.
Following the transaction, the number of shares in which John
Johnston has an interest remains unchanged at 120,583 Ordinary
Shares.
This announcement, including the notification below, is made in
accordance with the requirements of Article 7 of Regulation (EU) No
596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name John Johnston
============================================ ============================================
2 Reason for the notification
==========================================================================================
a) Position/status Non-Executive Director and PDMR
============================================ ============================================
b) Initial notification/Amendment Initial notification
============================================ ============================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==========================================================================================
a) Name MaxCyte, Inc.
============================================ ============================================
b) LEI
============================================ ============================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
==========================================================================================
a) Description of Ordinary shares
the financial
instrument, type
of instrument
============================================ ============================================
b) Identification
Code
============================================ ============================================
c) Nature of the Transfer of Ordinary Shares to spouse/PCA
transaction
============================================ ============================================
d) Price(s) and volume(s) Price(s) Volume(s)
============================================ ====================== ====================
e) Aggregated information N/A
- Aggregated volume 17,041
- Price
============================================ ============================================
f) Date of the transaction 14 December 2019
============================================ ============================================
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
============================================ ============================================
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Sukaina Virji
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, including with all of
the top ten global biopharmaceutical companies. The Company now has
more than 80 partnered programme licenses in cell therapy with more
than 45 licensed for clinical use, including five commercial
licenses. Aggregate potential pre-commercial milestones from all
license deals total more than $450m. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products. For more information, visit
www.maxcyte.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEAXAKFADNFFF
(END) Dow Jones Newswires
December 16, 2019 12:25 ET (17:25 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024